Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BMS-986393
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : BMS-986393
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enasidenib,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R/R AML
Details : Idhifa (enasidenib) is an isocitrate dehydrogenase-2 inhibitor, which is being evaluated in combination with venetoclax for the treatment of IDH2 gene mutated acute myeloid leukemia.
Product Name : Idhifa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2024
Lead Product(s) : Enasidenib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2024
Lead Product(s) : Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Bristol Myers Releases Data Reinforcing Zeposia's Efficacy in MS
Details : Zeposia (ozanimod) is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. It is indicated for relapsing forms of multiple sclerosis.
Product Name : Zeposia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CC-97540
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : CC-97540
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisocabtagene Maraleucel
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Breyanzi
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Lisocabtagene Maraleucel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Juno Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Luspatercept
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : University of Leipzig
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Luspatercept
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : University of Leipzig
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enasidenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Enasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Agreement
Sun Pharma Settles generic Revlimid Patent Litigation in US
Details : Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime...
Product Name : Revlimid
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable